University of Connecticut

OpenCommons@UConn
Master's Theses

University of Connecticut Graduate School

5-3-2017

Competing Risk Analyses for African American
and White Breast Cancer Patients
Amna Sarwar 4912423
University of Connecticut - Storrs, sarwar@uchc.edu

Recommended Citation
Sarwar, Amna 4912423, "Competing Risk Analyses for African American and White Breast Cancer Patients" (2017). Master's Theses.
1074.
https://opencommons.uconn.edu/gs_theses/1074

This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been
accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact
opencommons@uconn.edu.

Competing Risk Analyses for African American and White
Breast Cancer Patients

Amna Sarwar
B.A, University of Maryland, 2008

A Thesis
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Public Health
At the
University of Connecticut
2017

i

APPROVAL PAGE
Masters of Public Health Thesis

Competing Risk Analyses for African American and White
Breast Cancer Patients

Amna Sarwar, B.A.

.
Major Advisor______________________________
Dr. Helen Swede
Associate Advisor ____________________________
Dr. David Gregorio
Associate Advisor____________________________
Dr. Susan Tannenbaum

University of Connecticut
2017

ii

Table of Contents

Page Number

Introduction.……………………………………………………………….1
Research Aim………….…………...……………………………………..2
Background and significance……………………….…………………2
Hypothesis…………….…………………………………………………..6
Methods…………….……………………….……………………………..7
Results…………………………………………………………………….10
Discussion………………………………………………………………..12
Public Health Implication…………..…………………………….........15
Strengths and Limitations……………………………………………..16
Table 1……………………………………………………………………..17
Table 2……………………………………………………………………..18
Table 3……………………………………………………………….........19
Table 4………………..........................................................................20
Table 5……………………………………………………………………..20
Figure 1a,b………………………………………………………………..21
Reference…………………………………………………………………22

iii

ABSTRACT
Background: Overall survivability in breast cancer has improved in the past decade yet
African American Black (AA/B) patients still experience disproportionately higher
mortality compared to whites, with some studies showing a widening disparity.
Emerging evidence suggests that comorbidities might play an important role in
explaining this disparity. Few studies to date, however, have examined if comordbidities tend to be linked more with other causes of death versus breast cancer
pointing towards the need of better controlling of existing co-morbidities. Traditional
methods of assessing cause-specific deaths, however, are prone to error in causespecific outcomes due to censoring all other causes of deaths. Methods: We analyzed
data from the Connecticut SEER tumor registry (n=2558) with equivalent proportions of
AA/B and white patients, and a random subset (n=416) of these patients for whom a
medical record review was conducted, seventeen prognostic clinical conditions (e.g.,
heart disease, diabetes) listed in the Charlson Co-Morbidity Index (CCI) were identified.
We compared estimates of breast cancer specific mortality using Cox Proportional
Hazard Survival Analysis to calculate hazard ratios (HR) with the Subdistributional
Hazard method (SD-HR), which calculates hazard ratios taking into account other
causes of death. Results: AA/B patients were less likely to have no co-morbidities
compared to whites (58.9% vs. 82.8 %, respectively, p=<.0001). Among patients with
local stage disease, the traditional Cox Method showed comparable breast cancer
specific mortality risk for AA/B compared to whites in the full sample (HR=0.97 95% CI
0.87-1.08) whereas the subdistributional method showed an increase breast cancer
mortality risk for African Americans (SD-HR=1.43 95% CI 0.97-2.12). For regional
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stage, both estimates were statistically significant but a greater effect was observed
using the subdistributional method (SD-HR=1.31 95% CI 1.13-1.52 and SD-HR=1.84
95% CI 0.1.34-2.53). When the CCI score was added to analyses in the sub-sample, a
substantially reduced risk of breast cancer-specific death was observed for AA/B
patients compared to whites (SD-HR=0.17 95% CI 0.03-0.92) but no difference in risk
was observed when using the Cox Method (HR=0.97 95% CI 0.70-1.17). For patients
with Regional stage in the sub-sample, adding the CCI score to the Cox model revealed
no difference in breast cancer specific mortality (HR=0.98 95% CI 0.67-1.43) but was
suggestive of a higher risk when using the sub-distributional analysis (SD-HR=1.99 95%
CI 0.90-4.345). Conclusion: In the larger sample, a higher risk of breast cancer specific
mortality for AA/B patients was observed when using the sub-distribution analytical
method compared to the traditional survival analysis. Adding the Charlson Co-morbidity
Index into models, however, revealed a reduced risk of breast cancer specific death for
those with local disease suggesting that existing medical conditions might drive
mortality when the cancer burden is lower.
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Introduction:
Breast cancer survival disparities are puzzling given that African American Black
(AA/B) women are less likely to develop breast cancer compared to white women. The
Centers for Disease Control (CDC) reports that breast cancer is the second leading
cause of cancer deaths in African Americans (Black) women.3 Although mortality rates
from breast cancer have declined over the past decade for all ethnic groups, AA/B
continue to suffer a higher burden of death.3 For decades, African-American/Black
(AA/B) breast cancer patients between the ages of 45-60 have had a 60% greater death
rate than their white counterparts1. Eliminating this racial survival disparity in breast
cancer is a public health priority. By establishing sufficient evidence, targeted
interventions can be created at the health care level to improve survival rates.
Numerous studies have implicated the three-fold greater prevalence of the
aggressive Triple-Negative Breast Cancer (TNBC) subtype (i.e., HER2-ER-PR-) in
African American/Black (AA/B), compared to non-Hispanic Whites, in the differential
poor survival prognosis2. One TNBC study, however, found that the presence of comorbidities at diagnosis was comparably predictive of mortality as TNBC.1 Those
findings are consistent with emerging data that AA/B breast cancer patients with specific
types of co-morbidities might be at disproportionate risk of mortality.7,26 Though the
impact of co-morbidities in survival in breast cancer patients has been studied, analyses
of competing risk of death in the presence of existing co-morbidities has not been
assessed to date. That is, given relatively higher rates of co-morbidities among AfricanAmericans 3,7, it is of interest to determine if African-American breast cancer patients
are more likely to die from other causes of death (e.g., heart disease) versus breast
cancer, and if differences in cause of death suggest the need for better control of comorbidities. Traditional methods of assessing cause-specific death, however, are prone
to underestimate the cause of interest (e.g., death from breast cancer) because all other
causes of death are censored.46-47In our study, therefore, we will compare breastcancer specific mortality using the traditional statistical method (i.e., Cox Proportional
Hazards Survival Analysis) versus the subdistributional hazard ratio (SHR) model in
which mortality for breast cancer as well as other causes of death are estimated.
Additionally, use of the SHR model is appropriate in study samples consisting of older
1

patients where competing causes of death may be relatively high such is the case in
cancer patients, a disease of aging.46-47Therefore, it is important to consider models that
take in account competing events when estimating cause-specific mortality from breast
cancer.

Research Aims:
The primary aim of this research project is to conduct a survival analysis using the
subdistributional competing risks approach versus the traditional technique in a large
sample of breast cancer patients (n=2558) from the Connecticut Tumor Registry. We
will determine whether mortality is due to any cause of death or breast cancer as the
cause of deathSecond, in a sub-set of this sample (n=416) for whom we conducted a
chart review, we will perform a competing risks analysis accounting for existing comorbidities ascertained using the Charlson Co-Morbidity Index (CCI) measurement tool.

Background and Significance:
African-American status continues to be an independent predictor of poor breast
cancer outcome, even after accounting for socioeconomic factors (SES), inadequate
health care access9 and controlling for common treatment. While there is evidence that
reduced accessibility to healthcare and delays in treatment can explain survival
disparities,10-12 findings from a large cooperative national clinical trial with nearly
identical treatment and conditions, African American/black ethnicity still remained an
independent predictor of breast cancer outcomes13 suggesting that underlying biological
disease or other clinical factors, such as co-morbidities at diagnosis might play a role.
Competing Risks of Death. By analyzing both subdistributional and traditional causespecific models, we can compare their ability to estimate specific causes of mortality.
Some studies have indicated that since elder population (age>65) have a higher risk of
dying from any cause, rates of death from breast cancer might be erroneously
estimated in traditional analyses that do not account for other causes of death in
analyses.46-47 That is, AA/B breast cancer patients actually less prone to death from
breast cancer than are white patients because AA/B patients are dying disproportionally
more from other causes?
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Traditional analyses tend to show that AA/B patients are more likely to die from breast
cancer than whites, but that finding might be questioned when non-breast cancer
deaths are censored in traditional survival analyses. Examining this question is further
complicated if the age at diagnosis differs meaningfully between groups. Given the
effects of age on breast cancer incidents, death often occurs in the presence of
competing risk factors such as heart disease or diabetes.5 Because AA/B breast cancer
patients tend to be diagnosed at earlier ages, then the likelihood of a comorbid condition
could also differ. Generally in older breast cancer patients, death occurs in the presence
of competing risk factors such as, for example, heart disease or diabetes. 5
The likelihood of erroneous estimation of breast cancer specific mortality using
the traditional methods of analysis, such as the Kaplan-Meier method and Cox
Proportional Hazards Survival Analysis, is due to the stipulation of a binary outcome
variable: those who experience the event of interest (e.g., breast cancer), and those
who do not. Those who do not experience the event are labeled censored, which
includes those who are presumed alive and those who died from a different cause. 6,48
Understanding the reasons behind the greater mortality in African-American breast
cancer patients requires analyzing the death from other causes as well.5

Co-Morbidities and Mortality. In breast cancer patients older than 50 years, noncancer mortality exceeds breast cancer mortality. Severe co-morbidities in early stage
breast cancer has been associated with all-cause mortality and breast cancer-specific
mortality.8 Prior research shows that patients with serious comorbidities have outcomes
that are comparable to those observed in the later stages of tumor. 14 A Danish
nationwide study concluded that successful treatment of existing co-morbidities in
breast cancer patients can improve survival rates of the patients. 7 Non-cancer mortality
is higher in black patients than whites at ages younger than 70. 15 Another study showed
that carefully accounting for comorbid illnesses, particularly diabetes and hypertension,
explained much of the racial disparity in non-cancer mortality.16

Specific Co-Morbidities. 14 African American women are considered at higher risk of
chronic conditions such as diabetes, hypertension and cardiovascular disease.7
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Measures of specific comorbidities may reflect the survival outcome more clearly than
do summarized measures that often give the same weight to all morbidities despite their
different impact. Age-adjusted death rates for coronary heart disease and stroke has
been shown to be higher in African Americans.22 These factors can very well raise the
risk of overall mortality and breast cancer specific mortality.
In recent years, more and more researchers have started looking at co-morbidities at
diagnosis of breast cancer that may explain survival outcomes in black patients. These
conditions as previously mentioned can be preexisting diabetes, hypertension, obesity
and number of other common chronic diseases. Preexisting conditions, though
unrelated to breast cancer, can pose a great threat to overall survival. A Black/White
Cancer study has shown that uncontrolled co-morbidities have an adverse effect on
cancer treatment and cancer survival outcomes.25
African American women have suboptimal blood pressure control based on
Healthy People of 2010 standards. As many as 64% of African American women may
have uncontrolled hypertension.27 In Blacks, severe hypertension and targeted organ
complicated hypertension are more common than in whites. Both are associated with
cardiovascular disease. Black Americans have a much higher risk of experiencing
hypertension related complications such as nephropathy, stroke, heart failure and type
2 diabetes.28 A study conducted in 2007 across 12 southeastern states found that the
pattern of treatment of diabetes in Black patients results from “suboptimal
implementation of evidence-based hypertension treatment guidelines”.31 Randomized
controlled studies have shown adequate blood pressure control in African Americans
who receive and adhere to optimal evidence-based hypertensive treatment with dietary
changes, ruling out biological differences as the root cause. Similarly, diabetes in
combination with hypertension is also a major public health problem in African
Americans. African Americans with diabetes are three times more likely to have
uncontrolled hypertension than those without diabetes.29 The CDC estimates that black
women have a 90% higher prevalence of diabetes than white women. The burden of
diabetes disproportionally affects blacks with more black women ending up with endstage-renal diseases than white women. Black women have also had 22% highest
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hospitalization rate related to diabetes in the 1990s compared to black men and a
striking 215% higher than white women.30
A recent study showed that breast cancer patients with a history of diabetes have
an increased risk of breast cancer specific mortality.26 Results from this study estimated
a 2-fold increase in breast cancer-specific mortality if diabetes was not treated in breast
cancer patients. Similarly, history of myocardial infarction was found to increase the risk
of breast cancer specific mortality. This pattern was observed in African Americas,
Asian Americans and Latinas.26 Additionally, those with a history of diabetes had a
significantly elevated risk of breast cancer specific mortality without chemotherapy or
radiotherapy compared to those without a history of diabetes and without
chemotherapy. More so, breast cancer specific mortality was significantly elevated
among cases with diabetes that didn’t receive chemotherapy versus those without
diabetes and chemotherapy.26 Diabetes and hypertension have been strongly and
widely associated with obesity.33,34 More than 75% African American women are
overweight or obese.34

Tumor Burden and Biology. Advanced stage at diagnosis also has been examined as
an explanatory factor in survival disparity. African American women are typically
diagnosed at an advanced stage and at younger ages even though the mammography
utilization and screening rate is comparable in whites and blacks.18 Advanced disease,
however, does not explain the survival gaps because the survival disparities are found
within each stage and not just at the advanced stage level 3.
In the past decade, adverse tumor biology has emerged as a focus in breast
cancer disparities emerged.17 In particular, African American/black women have threefold greater prevalence of triple negative breast cancer (TNBC) compared to white
women 1,19 TNBC tumor lacks the expression of estrogen, progesterone and HER2
receptors in breast cancer cells. Receptors are found on cancer cells and attach to
certain substances such as hormones that circulate in the blood. Some breast cancer
cells have receptors that bind to estrogen or progesterone hormones. Estrogen and
progesterone hormones are both known to fuel the growth of breast cancer cells. Breast
cancer cells that either express receptors for estrogen or progesterone are known as
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hormone-receptor positive breast cancer. Almost 20% of breast cancer patients have a
breast cancer cell growth protein called HER2/neu that promotes the growth of cancer
cells. Breast cancer cells that express increased levels of HER2/neu proteins are
classified as HER2 positive and tend to grow more aggressively compared to other
cancers. The hormone receptor positive and HER2/neu positive breast cancer have
targeted hormonal therapy, and therefore have better prognosis.3 Because TNBC
tumors lack hormone receptors, no hormonal therapy is useful. When compared to
other subtypes of cancer tumors, TNBC tumors have been shown to result in
significantly worse prognosis outcomes9. However, a recent study shows that African
American women with breast cancer continue to experience survival disadvantages in
advanced disease whether or not the tumor expresses the TNBC subtype.20 This
evident suggests that other clinical and psychosocial factors must be studied to fully
understand the survival gap. Recently, presence of co-morbidities has emerged as a
potential risk factor for the African American women with breast cancer 21.

Hypotheses. Based on our prior research that showed evidence of co-morbidities being
the independent prognosis factor for African American with breast cancer 1, we
hypothesize that there is an association between co-morbidities and specific cause of
death in African American breast cancer patients. We anticipate that African Americans
are more likely to die of non-breast cancer related causes such as heart disease or
diabetes compared to white breast cancer patients. Hence, in our total sample
(n=2558), we predict that competing risk factor analyses will reveal differences in causespecific death mortality between blacks and whites. Second, given that it is likely that
the survival disparities in African Americans breast cancer patients might be due to the
higher chances of dying from the existing co-morbidities at breast cancer diagnoses, we
expect to see a positive relationship between the co-morbidity score and mortality
hazard ratio resulting from one or the combination of those co-morbidities as analyzed
in the sub-sample (n=416) of the chart review. We predict that these patterns will be
independent of TNBC status and breast cancer stage.
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METHODS: Study population: Our overall sample consists of all AA/B breast cancer
cases (ICD-O-3 C50.0-C50.9) diagnosed between January 1, 2000 and December
31,2007 and an age-matched random sample of an equivalent number of white
patients during the study period (n=2558). From this sample and a random sample
(n=416) medical record review on African American (AA/B) and White female breast
cancer patients. The random sample of 416 female breast cancer patients is derived
from our parent study (full sample) of 2558 patients diagnosed with primary breast
cancer (ICD-O-3 C50.0-C50.9) between January 1, 2000 and December 31, 2007 in the
State of Connecticut. Data were obtained from the Connecticut Tumor Registry (CTR),
a participant site in the NCI-SEER program. In statistical analyses for n=416, we
excluded patients who had missing data on age, race, TNBC status, comorbidity score,
vital status, Seer Summary stage advance/distant and those who were lost to follow up.
Access to medical records was approved by the Institutional Review Boards at
University of Connecticut Health Center, Yale Cancer Center, Hartford Hospital, and the
Human Investigation Committee at the Connecticut Department of Public Health.

Causes of Death: Case records were followed untill December 2015 for vital statuses
including causes-of-death. Causes of deaths were grouped into five categories including
breast cancer, cardiovascular diseases, non-cardiovascular diseases, other cancers
and unknown causes.
Descriptive Analyses: Clinicopathological characteristics between white and AA/B
patients are compared for full sample (n=2558) and random sample (n=416) using χ2
test for the following categorical variables: age, histological subtype, SEER summary
stage, tumor grade and TNBC. SEER summary stage distant will be excluded from
parent population for survival analyses.

Clinicopathological Data. Information in the CTR database includes: ER, PR, age at
diagnosis, SEER Summary Stage (local, regional) and ICD-O-3 histologic subtypes.
Local stage is defined in SEER as invasive cancer confined to the breast; and, regional
stage is defined, as cancer detected to have spread to the axillary lymph nodes or
contiguous tissue. Information about first-course of chemotherapy is available in the
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CTR database, although in recent years SEER no longer makes this information
available in the public dataset due to substantial missing data and unreliability of the
information.37 TNBC status was derived from both the CTR database (i.e., ER, PR) and
abstraction of summary pathology reports (i.e., HER2) at the registry as described in our
previous investigations using this study sample.28

Co-Morbidity Information. Medical conditions were abstracted using the validated
Charlson Co-Morbidity Index (CCI), a weighted list of 17 items developed in 1987 40 and
a prominent tool in cancer research.41 The CCI includes measurement of myocardial
infarction, congestive heart failure, peripheral vascular disease, cerebral vascular
disease, dementia, chronic lung disease, rheumatologic disease, peptic ulcer disease,
mild liver disease, diabetes without complications, diabetes with complications,
hemiplegia, neoplasia, moderate/severe liver disease, metastatic disease, human
immunodeficiency virus, and renal disease. A cumulative score is calculated based on
a no (0) or yes (1) for each condition, and weighted according to a specific protocol.40
Briefly, the weight applied to a particular condition reflects the associated hazard ratio of
death within one-year of cancer diagnosis.
Due to emerging evidence of the prognostic importance of hypertension in
distinguishing mortality risk in cancer survival disparities38, we adopted the CCI
following an approach in Braithwaite and Tammemagi39 to assign an additional point by
including high blood pressure (CCI+HBP) as comorbidity. Scores for the CCI (0-17) and
CCI+HBP indices were employed in statistical analyses as either a continuous or
categorical variable (0, 1-2, ≥ 3). We will look at the weight distribution of AA/B and
whites for CCI score with hypertension and compare the differences between the two.

Competing Risks Survival Analyses: Survival time is measured for all patients as the
duration of date of diagnoses to date of death or last follow up. When conducting a
competing risk analyses, patients still alive at the date of last follow up are considered
‘censored’ and those who died of a disease under study are considered an ‘event’.
Patients who die of an unrelated cause are considered competing risk events.6
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Kaplan-Meier or cause-specific method estimates the distribution of time to event of
interest such as death from breast cancer and ignores all the other events This method
censors all competing events and may yields biased results. While a cause-specific
model is better suited for examining the etiology of diseases, the subdistributional
hazard ratio model is more useful in predicting an individual’s competing-risks.35 In this
model, those subjects that experience a competing risk event are retained even after
the competing event but with gradually decreasing weight.35-36 We used The Fine and
Gray subdistributional hazard ratio (described elsewhere)35 to compare the absolute
mortality risk for breast cancer and all-cause deaths for the full sample (n=2558) and to
asses AA/B versus White breast cancer patients’ mortality in the presence of competing
risks by age and tumor size for local and regional stages. Briefly, in this model the
hazard ratio is based on a modified risk set where those subjects that experience a
competing event remain in the risk set even after experiencing that event. The weight of
the subjects that are retained in the risk set artificially reduces gradually. SAS edition
9.0 was used for Phreg functions analyzing subdistributional hazard ratio and standard
cox/cause specific hazard model.42 We also applied the subdistributional hazard model
for breast cancer and all cause deaths in AA/B verses White breast cancer patients by
age, tumor size for the subset analyses (n=416) with and without co-morbidity index
score in the model. We used the standard cox regression/cause-specific hazard model
for all-cause mortality and by breast cancer-specific death in AA/B and white breast
cancer patients by multivariate age and tumor size for the full sample. Cause-specific
hazard model was used for the sub-sample (n=416) by multivariate age and tumor size
with and without Co-morbidity score (+/-). In order to infer the added benefits of comorbidity in analyzing competing risk hazard ratio for breast cancer, we compared the
differences in hazard ratio using cause-specific model and subdistributional model for
breast cancer specific mortality in AA/B and Whites between full sample and subsample with co-morbidity index score at the local stage.
Next, we explored all-cause and breast cancer specific Co-morbidity index hazard ratio
using cause-specific model for AA/B and whites by multivariate age, co-morbidity index
score, and tumor size at local and regional stages in the presence of competing event.

9

Risks to human subjects: Data collected for this project is from Connecticut tumor
registry located in the department of public health. By legislation law, all licensed
Connecticut hospitals are required to provide information on cancer incidence,
treatment and follow up. The Connecticut General Statue 19a-25 protects the identities
of all the human subjects/patients. Confidentiality and privacy of subjects is approved by
the Investigations Committee of the Connecticut once reviewing the study’s protocol,
methods and procedures for protecting the patient’s privacy and confidentiality.
Completely anonymous data is used with unique study ID numbers for all individuals to
safeguard subject’s privacy. No such data is used that might lead to a particular
individual’s bio-data.

RESULTS
In the total sample n=2558 (Table1), the most common histology subtype in both whites
and AA/B was ductal (67.1% and 68.6%, respectively) yet the overall histological
patterns were statistically significant (P <.0001 omnibus) due to variations in prevalence
of lobular and medullary sub-types. Compared to black patients, white patients were
almost twice as likely to have lobular histology, which is comparatively more favorable
histology (10.3% vs. 5.6%, respectively, p<0.0001) and less likely to be diagnosed with
the more aggressive medullary breast cancer (0.4% vs. 8.1%, p<.0001). Similar trends
were observed in the n=416 subsample (Table 1). As expected, white patients were
more likely than blacks to have early stage disease in both the full (65.8% vs. 57.1%,
respectively, p<0.0001) and sub-sample (68.7% vs. 62.0%, respectively p=.0.209) but
the difference reached statistical significance in the full sample (Table 1). AA/B breast
cancer patients had a higher prevalence of TNBC in the total sample as well as
subsample n=416 (30.3% vs. 12.8% p<0.0001 and 26.0% vs. 16.4% p<.001)

Charlson Co-Morbidity Index (n=416 sub-sample):
AA/B breast cancer patients were more likely to have higher CCI scores (Table 2,
omnibus p<.0001) as determined by the weighted sum of conditions present within oneyear (before and after) the breast cancer diagnosis. Specifically, substantially more
white breast cancer patients had no existing co-morbidity compared to black patients
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(82.7 % vs. 58.9%, respectively, p,.0001); 25.7% of AA/B had a CCI score of 1-2
compared to only 11.2% of whites (p<0.0001); and, proportionally more AA/B
Americans had CCI scores of 3 or more compared to their white counterparts (15.3%
vs. 6.1% p<0.0001). When hypertension was added to the index, the proportion of AA/B
patients without any co-morbidity decreased by one-third (58.9% to 39.1%), and, for
white patients, the drop was about one-fourth (82.7% to 60.7%).

Causes of Death:
The median survival time after diagnosis was comparable (10.4 vs. 10.2 yrs) for both
AA/B and whites in the full and sub-samples (Table 3). While breast cancer was the
leading cause of death in both AA/B patients and white patients in the sub-sample
(Table 3), somewhat more AA/B patients died of breast cancer compared to whites
(50.7% vs 43.8%, omnibus P=.810)

All-Cause Hazard Ratio:
Among patients diagnosed with local stage of breast cancer (i.e., tumor has not spread
to regional lymph nodes), AA/B did not appear to be at increased risk of mortality
compared to whites in the full (Crude HR=0.973, 95% CI 0.872-1.087) or sub-sample
(Crude HR=0.955, 95% CI =0.741-1.231) (Table 4). When adding the standard CCI
score to the analysis, the HR estimate did not appreciably change. At the regional
stage, AA/B patients were found to be at increased risk for overall death in full sample
(HR=1.310, 95% CI= 1.128-1.522). Regarding patients diagnosed with regionally
advanced breast cancer, adding CCI did not change the all cause mortality ratio for
AA/B women (HR=1.006, 95% CI= 0.691-1.466).

Breast Cancer Specific Hazard Ratios
For the full sample, as seen in Table 5, blacks were more likely to die from breast
cancer when analyzed with the sub-distribution analysis methodology (SD-HR=1.434
95% CI 0.969-2.122) yet no effect was revealed using the traditional Cox Proportional
Hazards Survival analysis (HR= 0.966, 95% CI=0.865-1.079). This difference in
findings, however, was not observed when analyzing the sub-sample in which no black-
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white difference in survival was observed by either method. When adding the CCI score
to the model, the traditional method revealed no black-white difference in dying from
breast cancer yet the risk of death from breast cancer among blacks compared to
whites was significantly reduced when using the subdistributional model (HR=0.168,
95% CI 0.0310-0.902).
For patients diagnosed with regional disease in the full sample, AA/B show an
increased risk of death from breast cancer compared to whites (HR=1.307, 95%
CI=1.125-1.519). Subdistributional model also shows a heightened increased risk of
breast cancer specific mortality for AA/B at regional stages (HR=1.841, 95% CI 1.3392.530). Adding CCI in the multivariate model suggests an increased risk of breast
cancer specific mortality for AA/B compared to whites when using the sub-distribution
model only (HR=1.999, 95% CI 0.902-4.346). Findings in Table 5 are illustrated
graphically in Fig 1.a (full sample) and Fig 1.b (sub-sample).
Risk of breast cancer specific death in relation to Charlson Comorbidity: As an
independent factor, the CCI was associated with statistically significant increases in the
hazard ratio per one unit score using both statistical methods for patients with local
disease (HR=1.363 95% CI 1.223-1.518 and SD-HR=2.088 95% CI 1.633-2.67) and for
regional disease (HR=1.132 95% 1.034-1.240 and SD-HR 1.167 95% CI 1.063-1.280).

DISCUSSION:
In order to diminish inequities in survival among breast cancer patients, it is
important to understand the role that existing co-morbidities play in mortality given
higher rates of various conditions among AA/B patients. We addressed this issue in two
ways: 1) Incorporating a co-morbidity score (CCI) into multivariate analyses; and, 2)
Assessing if African-Americans tend to die at a higher proportion from breast cancer
versus co-morbidities (e.g, heart disease). Additionally, when evaluating cause-specific
deaths, we compared the use of traditional cox-regression model, which censors nonbreast cancer deaths with the subdistributional hazard model, which takes into account
all causes of deaths.
Descriptive Analyses. Using the Charlson Co-Morbidity Index, our descriptive
analyses showed that African Americans breast cancer patients were far more likely to
have an existing co-morbidity at the diagnosis compared to whites. Specifically, about
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41% of AA/B patients had at least one co-morbidity at diagnosis compared to 17% of
whites. This prevalence appears somewhat consistent with a Medicare claim data
analyses that had shown that almost 42% of patients diagnosed with breast cancer has
one or more co-morbidities.46 This difference in comorbidities at the diagnoses of breast
cancer is not due to the differences in age between AA/B and whites. Whites are
diagnosed at an older age and should have higher number of existing comorbidities yet
AA/B still experience higher rates of existing comorbidities despite being diagnosed with
breast cancer at a younger age. The Charlson co-morbidity index does not include
hypertension in its 17-listed comorbidities, and based on a prior study by Braithwaite et
al39 we added hypertension for comparative analyses. As expected, the score for AA/B
breast cancer patients increased disproportionally compared to the increase in white
patients.
Causes of death between African American and whites showed marked differences as
well. In the larger study group (n=2558), AA/B experienced higher rates of death from
breast cancer compared to whites. However, in the smaller group of n=416 with
comorbidity index included, the difference between blacks and whites was reduced. A
possible reason could be that rate of co-morbidities differed between the two study
samples, although we employed a randomization scheme to create the smaller sample
for the chart review. We base this hypothesis on prior studies that have shown,
paradoxically, that delays or under treatment for conditions such as diabetes and
myocardial infarction can actually result in increased breast cancer specific mortality26.
More so, it is well-established that AA/B have a higher prevalence of undertreated and
uncontrolled diabetes. 31
Survival Analyses. We employed the traditional Cox Proportional Hazards regression
model and, for comparison, the subdistributional hazard model, which has been found
to provide a more accurate estimate of risk when there is a high degree of deaths from
other causes in the study population (i.e., competing risks).46-48 Among patients
diagnosed with Local Stage disease, when the traditional Cox method with breast
cancer specific mortality as the end-point (all other endpoints censored) was employed
in the larger sample (n=2558), we observed comparable mortality risks for African
American and whites (HR=0.966 95% CI 0.865-1.079), yet the subdistributional method
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showed an increase in breast cancer mortality risk for African Americans (SD-HR=1.434
95% CI 0.969-2.122). The corresponding estimates for Regional Stage were (HR=1.307
95% CI 1.125-1.519 and SD-HR=1.841 95% CI 0.1.339-2.530). It appears, therefore,
that the traditional model appears to have indeed overestimated hazard mortality for
whites. On the other hand, the analyses for the small sample (n=416), did not show
these patterns, and showed a reduced risk of breast cancer specific mortality among
blacks compared to whites (SD-HR=0.17 95% CI 0.03-0.92) at the local level. The Cox
method however revealed no differences (HR=0.97 95% CI 0.70-1.17).
Regarding the addition of co-morbidity scores into the multivariate models, we
observed that at the local stage breast cancer-specific mortality for AA/B was
significantly reduced suggesting that existing comorbidities might drive mortality when
the cancer burden is low. Racial disparities in breast cancer-specific mortality were also
noted when using the subdistribution analysis in Regional Stage with higher breast
cancer-specific mortality, pointing towards a greater burden of death at the advancing
stage. The impact of comorbidities is prevalent in local stage versus the regional stage
possibly due to the increased mortality risk resulting from the added anatomical burden
of regional disease. This is consistent with our previous findings from 2015 that
emphasized the role of existing conditions as playing a role for AA/B in worsening their
survival outcomes particularly at the local stage level. Prior studies also have shown
that the presence of a co-morbidity at the time of diagnosis of breast cancer have
significantly worse survival outcomes.14 The combined effects of advanced stage and
existing comorbidities for AA/B compared to whites suggests a possible additive or
multiplicative effect.
Our findings are not consistent, however, with Schairer and colleagues who have
shown a lower breast cancer specific mortality at regional stage with advanced age.
Other studies have shown a larger effect of all cause mortality with advancing age. 50-51.
While Schairer et al did not account for comorbidities, they speculated that higher
probability of death from breast cancer and other causes in blacks compared to whites
might also be attributed to obesity related morbidities.49 Breast cancer-specific mortality
showed results that were independent of age, breast cancer subtype and race. AA/B
race was not a prognostic factor for worsening breast cancer-specific mortality hazard
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ratio but rather the advancing stage and comorbidities seem to play a role. Adding the
Charlson Co-morbidity Index in the model showed significant differences for AA/B risks
for breast cancer mortality at the local stage. Other studies have also shown an
increase in mortality rate from other causes with advancing age.49-50 There are also
reports that look at 5 to 8 year relative survival showing no decline in breast cancer
mortality with advancing age.51-52
Further exploration can point towards treatment differences, poorly controlled
conditions and possibly genetic differences such as higher prevalence of sickle cell
anemia. African Americans have a high prevalence of sickle cell trait. Results from
National Surgical Adjuvant Breast and Bowel Project (NSABP) showed that stage and
pathological differences did not fully account for differences in outcome between African
Americans and white women with breast cancer. In addition when stage and treatment
was comparable, blacks and white breast cancer patients had similar outcomes.
Despite the fact that clinical differences are important for breast cancer survival
prognosis, appropriate and timely treatment may yield better outcomes for African
American women with breast cancer.43 Previous literature review and case reports have
shown adverse events in breast cancer patients with sickle cell trait possibly due to
higher chances of hypoxia and sickling resulting from cancer therapy. Literature
indicates that in the presence of sickle cell trait, enhanced patient monitoring and
treatment adjustment is needed. Furthermore, genotyping might be another necessary
step for African Americans with breast cancer prior to treatment. 44-45
African women also experience high CCI hazard ratio breast-cancer specific mortality
rate due to existing comorbidities at the local stage. White Americans with the same
comorbidity index score, not showing the same detrimental increase in CCI hazard
compared to African American women, may indicate that presence of poorly controlled
conditions like hypertension, cardiovascular disease and diabetes can be responsible
for worse breast cancer specific outcomes for African Americans. It may also be due to
certain genetic predispositions such as sickle cell trait that has been overlooked. In
addition, it reinforces the need to further investigate the clinical and pathophysiological
differences in existing conditions between different racial groups.
Public health implications:
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Complex and interwoven factors contribute to observed disparities in breast cancer
deaths among racial and ethnic minorities. The probability of death from causes other
than breast cancer in the presence of competing risks appears to be a more accurate
measure of mortality across different ethnicity/racial group. While socioeconomic factors
have been under extensive study, existing conditions such as cardiovascular disease
and diabetes are the emerging competing risks that play a role in cancer survival and
treatment. One of the main goals of public health is to eliminate health disparities using
improved prognostic information by assessing the burden of mortality from breast
cancer and other causes by race and comorbidities. Studying breast cancer survival
differences among the racial minority help us draw a map of the contributing factors and
their possible solution. This study will help to elucidate if AA/B and white differ in
competing risks for breast cancer mortality and all-cause mortality. By understanding
the risks, we can focus on reducing these risk factors in both African American and
white breast cancer patients.
Strengths and Limitations:
We had multiple strengths in our study. Our population was derived from reputable NCISEER Tumor registry of Connecticut. One of the strength of our analyses was
establishing a comorbidity index score for our breast cancer patients with the addition of
hypertension, which confirmed higher rates of co-morbidities scores for AA/B vs. Whites
at the time of breast cancer diagnoses. Our n=416 sample was comparable to our larger
study population and showed similar histopathological findings. More so, our
histopathological findings such as TNBC subtype and tumor subtypes were concurrent
with other cancer survival studies. There are two main limitations to this study. One
limitation of this study was sample size due to which we were not able to look at specific
co-morbidities such as diabetes and myocardial infarction separately. Another limitation
that came with the small sample was not having large enough numbers of
cardiovascular or diabetes deaths. Therefore, the causes of death had to be studied as
breast cancer versus non-breast cancer. Lack of treatment data is another potential
limitation given that a number of studies have shown that different treatment patterns
may explain some survival disparities in breast cancer.
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Table 1a:

Clinicopathological Characteristics of Breast Cancer Patients
(According to Race, Age, NCI SEER Tumor Registry, and TNBC)
N=2558

Age
<=40
>40
Mean Age
(SD)
Histological Subtype *
Ductal
Lobular
Mixed (Ductal, Lobular )
Medullary
Other

SEER Summary Stage
Local
Regional

TNBC subtype
ER- PR- HER2ER- PR- HER2+
ER / PR+ HER2ER / PR+ HER2+

White
n=1405

AA/B
n=1152

80
5.8%
1285
94.1%
62
54.9%

123
10.8%
1011
89.1%
57
45.1%

907
67.1%
139
10.3%
191
14.1%
6
0.4%
109
8.1%

777
68.6%
63
5.6%
143
12.6%
33
2.9%
116
10.2%

885
65.8%
393
29.2%

637
57.1%
411
36.9%

117
12.8%
39
4.3%
637
69.7%
121
13.2%

243
30.3%
80
10.0%
397
49.6%
81
10.1%

N=416
P-Value

<.0001

.721

<.0001

<.0001

<.0001

White
n=214

AA/B
n=202

11
5.1%
203
94.8%
58
51.4%

30
14.8%
172
85.1%
55
48.6%

124
57.9%
24
11.2%
52
24.3%
2
0.9%
12
5.6%

127
62.9%
12
5.9%
37
18.3%
4
2.0%
20
10.9%

145
68.7%
66
31.3%

119
62.0%
73
38.0%

35
16.4%
6
2.8%
143
66.8%
30
14.0%

52
25.7%
20
9.9%
117
57.9%
13
6.4%

P-Value

0.005

<.0001

0.043

0.209

<0.0001
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Table 2 CCI score with and without HBP (n=416)

CCI score
0
1-2
3+

CCI score with HBP
0
1-2
3+

White

Black

177
82.7%
24
11.2%
13
6.1%

119
58.9%
52
25.7%
31
15.3%

130
60.7%
64
29.9%
20
9.3%

79
39.1%
84
41.6%
39
19.3%

P Value

<.0001

<.0001
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Table 3 Vital Status, Survival and Cause of Death in relation to Whites and AA/B

N=2558
White
Black
Alive

913
65.4%

687
60.5%

10.2

Breast Ca

Other Ca

P-Value

166
77.6%

31
65.8%

10.4

9.7

10.3

182
37.7%

225
50.1%

21
43.8%

35
50.7%

63
13.0%

55
12.2%

8
16.7%

8
11.6%

CVD

86
17.8%

64
14.3%

6
12.5%

7
10.1%

Non-CVD
and Other/Unk

152
31.5%

105
23.3%

13
27.1%

19
27.5%

Median Survival
(years)
Cause of Death

.011

N=416
White
Black

.001

P-Value

.008

.810
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Table 4 Multivariate* All-Cause Hazard Ratios and 95% CIs with and without
Charlson Co-Morbidity Index (CCI)
n=2558

n=416

n=416

Black vs. White
HR
.973
0.872-1.087
-

Black vs. White
HR
0.955
0.741-1.231
0.906
0.700-1.173

Black vs. White
CCI HR

1.310
1.128-1.522
-

1.088
0.753-1.572
1.006
0.691-1.466

Local Stage

No CCI
With CCI

1.363
1.223-1.518

Regional Stage
No CCI
With CCI

1.129
1.032-1.236

Table 5 Multivariate* Breast Cancer Specific Hazard Ratios and 95% CIs with and
without Charlson Co-Morbidity Index

n=2558

HR

n=416

SD-HR

HR

SD-HR

0.955
0.739-1.233

0.870
0.290-2.613

0.906
0.700-1.173

0.168
0.031-0.902

1.061
0.733-1.535

2.378
1.106-5.113

0.980
0.671-1.429

1.999
0.902-4.346

Black vs White
Local Stage
No CCI

0.966
0.865-1.079

1.434
0.969-2.122

With CCI

Regional Stage
1.307
No CCI
1.125-1.519

1.841
1.339-2.530

With CCI

CCI HR
Local Stage

1.363
1.223-1.518

2.088
1.633-2.670

Regional Stage

1.132
1.034-1.240

1.167
1.063-1.280
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Fig 1a.

Breast Cancer-Specific Subdistritbutional vs. Cox Hazard
ratio at Regional Seer Stage N=2558
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Fig 1b.
Breast Cancer-Specific Subdistritbutional vs. Cox Hazard ratio at
Regional Seer Stage N=416
SD-HR-Blacks

Cox-Blacks

COX

B

0

0.5

1

1.5

2

SD-HR

B
2.5

3

3.5

4

4.5

5

HAZARD RATIOS

.

21

Reference:

1. Swede H, Gregorio DI, Tannenbaum SH, Brockmeyer JA, Ambrosone C, Wilson LL,
Pensa MA, Gonsalves L, Stevens RG, Runowicz CD. Prevalence and prognostic
role of triple-negative breast cancer by race: a surveillance study. Clin Breast
Cancer 2011;11:332-41.

2. Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer.
The New England Journal of Medicine, 363(20), 1938-1948.

3. Cancer Facts & Figures for African Americans, 2011-12. , 2013.

4. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer
J Clin 2011;61:409-18.

5. Rosenberg MA. Competing risks to breast cancer mortality. J Natl Cancer Inst
Monogr. 2006;(36):15-9.

6. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, A note on competing
risks in survival data analysis. British Journal of Cancer (2004) 91, 1229–1235.
7. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D.
Comorbidity and survival disparities among black and white patients with breast
cancer. JAMA 2005;294:1765-72.
8. Ording AG, Garne JP, Nystrom PM, Froslev T, Sorensen HT, Lash TL. Comorbid
diseases interact with breast cancer to affect mortality in the first year after
diagnosis--a Danish nationwide matched cohort study. PLoS One.
2013;8(10):e76013
9. Du, X. L., Lin, C. C., Johnson, N. J., & Altekruse, S. (2011). Effects of individual-level
socioeconomic factors on racial disparities in cancer treatment and survival:
Findings from the national longitudinal mortality study, 1979-2003. Cancer, 117(14),
3242-3251.
10. Ademuyiwa FO, Edge SB, Erwin DO, Orom H, Ambrosone CB, Underwood W,3rd.
Breast cancer racial disparities: unanswered questions. Cancer Res 2011;71:640-4.

22

11. Masuo K. Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension
and metabolic syndrome. Int J Hypertens. doi: 2010;2010:832821
12. Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in adjuvant chemotherapy
treatment among patients with breast cancer are more likely in African American and
Hispanic populations: a national cohort study 2004-2006. J Clin Oncol
2010;28:4135-41.
13. Albain KS, Unger JM, Crowley JJ, Coltman CA,Jr, Hershman DL. Racial disparities
in cancer survival among randomized clinical trials patients of the Southwest
Oncology Group. J Natl Cancer Inst 2009;101:984-92.
14. Patnaik JL, Byers T, DiGuisepppi C, Denberg TD, Dabelea D The influence of
comorbidities on overall survival among older women diagnosed with breast
cancer.J Natl Cancer Inst. 2011;103(14):1101-1111.
15. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer
and other causes among female breast cancer patients. J Natl Cancer
Inst. 2004; 96: 1311-1321.
16. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D.
Comorbidity and survival disparities among black and white patients with breast
cancer. JAMA 2005;294:1765-72.
17. Ademuyiwa FO, Edge SB, Erwin DO, Orom H, Ambrosone CB, Underwood W,3rd.
Breast cancer racial disparities: unanswered questions. Cancer Res 2011;71:640-4.
18. Sabatino SA, White MC, Thompson TD, Klabunde CN. Cancer screening test use United States, 2013. MMWR Morb Mortal Wkly Rep 2015;64:464-8.
19. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg
EW, O'Regan RM, Gabram SG, Eley JW. Race and triple negative threats to breast
cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat
2009;113:357-70.
20. Swede H, Sarwar A, Magge A. 2Braithwaite D, 3Cook LS, 1Gregorio DI, 4Jones BA.
Mortality Risk from Co-Morbidities independent of Triple-Negative Breast Cancer
Status: NCI SEER-based Cohort Analysis. Cancer Causes and Control. Under
review, 2015

23

21. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer
treatment and survival. J Natl Cancer Inst. 2002;94(7):490-496.
22. Statistical fact sheet, 2013. Retrieved from:
<https://www.heart.org/idc/groups/heartpublic/@wcm/@sop/@smd/documents/down
loadable/ucm_319568.pdf>
23. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J
Clin. 2014;64(1):52-62.
24. Schillinger D, Sarkar U. Numbers don't lie, but do they tell the whole story? Diabetes
Care. 2009;32(9):1746-1747.
25. Muss HB, Hunter CP, Wesley M, et al. Treatment plans for black and white women
with stage II node-positive breast cancer. The National Cancer Institute
26. Wu AH, Kurain AW, Kwan ML, John EM, Lu Y, Keegan TH, Diabetes and Other
Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast
Cancer Survivorship Consortium (CBCSC). Cancer Epidemiol Biomarkers
Prev February 201524:361-368
27. Jackson JH, Bramley TJ, Chiang TH, Jhaveri V, Frech F. Determinants of
uncontrolled hypertension in an African-American population. Ethn Dis.
2002;12(4):S3-53-7.
28. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in
African Americans: Consensus statement of the hypertension in African Americans
working group of the international society on hypertension in blacks. Arch Intern
Med. 2003;163(5):525-541.
29. McDonald MV, Pezzin LE, Peng TR, Feldman PH. Understanding the complexity of
hypertensive African American home care patients: Challenges to intervention. Ethn
Dis. 2009;19(2):148-153.
30. Herman WH, Thompson TJ, Visscher W, et al. Diabetes mellitus and its
complications in an African-American community: Project DIRECT. J Natl Med
Assoc. 1998;90(3):147-156.
31. Sampson UK, Edwards TL, Jahangir E, et al. Factors associated with the prevalence
of hypertension in the southeastern United States: Insights from 69,211 blacks and

24

whites in the Southern Community Cohort Study. Circ Cardiovasc Qual Outcomes.
2014;7(1):33-54.
32. Masuo K. Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension
and metabolic syndrome. Int J Hypertens. doi: 2010;2010:832821
33. Masuo K. Obesity-related hypertension: Role of the sympathetic nervous system,
insulin, and leptin. Curr Hypertens Rep. 2002;4(2):112-118.
34. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of
sympathetic activation in obesity-related hypertension. Hypertension.
2006;48(5):787-796
35. Lau B, Cole SR, Gange SJ, Competing Risk Regression Models for Epidemiologic
Data
36. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and
conditional failure probabilities—examples from clinical oncology data. J Am Stat
Assoc. 1993;88(422):400–409
37. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL.
Comparison of SEER Treatment Data With Medicare Claims. Med Care 2014;.
38. Pensa M, Swede H, Brockmeyer JA, Gregorio DI. Patterns of HER2 testing in the
management of primary breast cancer. Cancer Epidemiol 2009;33:113-7.
39. Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West
DW, Satariano WA, Liebman M, Esserman L. Hypertension is an independent
predictor of survival
40. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation. J Chronic
Dis 1987;40:373-83.
41. . de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity.
a critical review of available methods. J Clin Epidemiol 2003;56:221-9.
42. Ying So, Guixian Lin, and Gordon Johnston, SAS. Using the PHREG Procedure to
Analyze Competing-Risks Data. 2014 SAS Institute Inc.
43. Dignam JJ. Differences in breast cancer prognosis among African-American and
Caucasian women. CA Cancer J Clin 2000;1:50-64.

25

44. Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS,Steinberg MH. Framing
the research agenda for sickle cell trait: building on the current understanding of
clinical events and their potential implications. Am J Hematol 2012;87:340–346.
45. Swede H, Biree A, Gregorio DI, Jones BA, Braithwaite D, Rohan TE, Stevens RG.
Adverse events in cancer patients with sickle cell trait or disease: case reports.
Genetics in medicine 2015; 237-241.
46. Berry SD, Ngo L ,Samelson EJ ,Kiel DP . Competing risk of death: an important
consideration in studies of older adults. J Am Geriatr Soc. 2010;58:783–787.
47. Pallis AG, Ring A ,Fortpied C et al. EORTC workshop on clinical trial methodology in
older individuals with a diagnosis of solid tumors. Ann Oncol.2011;22:1922–1926.
48. de Glas N. A, Kiderlen M, Vandenbroucke J. P, de Craen A. J. M, Portielje J. E.
A,van de Velde C. J. H, Le Cessie S .(2016). Performing survival analyses in the
presence of competing risks: A clinical example in older breast cancer
patients.Journal of the National Cancer Institute, 108, djv366.
http://jnci.oxfordjournals.org/content/108/5/djv366.abstract

49. Schairer C, Mink PJ, Carroll L, et al. Probabilities of death from breast cancer and
other causes among female breast cancer patients. J Natl Cancer Inst 2004;96:13111321
50. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age
and comorbidity in postmenopausal breast cancer patients aged 55 and
older.JAMA 2001;285:885–92.
51. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of
elderly women with breast cancer. J Natl Cancer Inst 2000;92:550–6
52. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al.
(editors).SEER cancer statistics review, 1975–2000. Bethesda (MD): National Cancer
Institute; 2003
53. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013
Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and
Human Services, Centers for Disease Control and Prevention, and National Cancer
Institute; 2016. Available at:http://www.cdc.gov/uscs.

26

